Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States-Reference-Cited by-同舟云学术

Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States

Published:2023-02-13 Issue:2 Volume:23 Page:197-206
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Bhambri Rahul,Colavecchia A. Carmine,Bruno Marianna,Chen Yong,Alvir Jose,Roy Anuja,Kemner Jason,Crowley Aaron,Benjumea Darrin,Gilstrap Lauren

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40256-022-00563-4.pdf

Reference30 articles.

1. Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2021;3:488–505. https://doi.org/10.1016/j.jaccao.2021.06.006.

2. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872–91. https://doi.org/10.1016/j.jacc.2019.04.003.

3. Nativi-Nicolau J, Judge DP, Hoffman JE, Gundapaneni B, Keohane D, Sultan MB, et al. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021;8:3875–84. https://doi.org/10.1002/ehf2.13541.

4. Rozenbaum MH, Large S, Bhambri R, Stewart M, Young R, van Doornewaard A, et al. Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy. J Comp Eff Res. 2021;10:927–38. https://doi.org/10.2217/cer-2021-0071.

5. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222-8.e1. https://doi.org/10.1016/j.ahj.2012.04.015.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis;ESC Heart Failure;2024-08-24

2. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis;eClinicalMedicine;2023-09